RenovoRx, Inc. (RNXT) stock
RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30163% above fair value
$1.16−0.06 (-4.92%)
Close on Nov 12, 2026Market cap $52.35MP/E –Yield –
RenovoRx ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
RenovoRx's ebitda for the twelve months ending Mar 31, 2026 was -$10.87M. For fiscal 2025 it was -$10.51M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.51M | – |
| FY2024 | Dec 31, 2024 | -$10.97M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -$3.47M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.52M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.20M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.68M | – |
See a number that looks wrong?